NEW YORK (GenomeWeb) – Promega Biotech India, a subsidiary of Promega Corporation, and Gurgaon, India-based laboratory Core Diagnostics have entered into a collaboration to make available Promega’s microsatellite instability test to guide the use of cancer immunotherapies.
Financial terms of the deal were not disclosed.
Promega’s MSI Analysis System uses fluorescent multiplex PCR to co-amplify seven markers for analysis of the MSI-high phenotype. The company claims that it offers greater accuracy than immunohistochemistry, with greater speed and lower costs than next-gen sequencing, in identifying MSI-high samples.
Promega said it intended to seek US Food and Drug Administration approval and CE-IVD marking for assay after the FDA granted accelerated approval to Merck’s PD-1/PD-L1 inhibitor Keytruda (pembrolizumab) for patients with MSI-high tumors last year.
Other genetic technologies that Core has adopted include liquid biopsy assays using Precipio’s ICE COLD-PCR platform, and genetic risk testing and blood-based colorectal cancer screening tests developed by CellMax Life.